(CORT) Corcept Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2183521028
Stock: Medications, Treatments, Disorders, Drugs
Total Rating 22
Risk 87
Buy Signal -1.82
| Risk 5d forecast | |
|---|---|
| Volatility | 60.3% |
| Relative Tail Risk | -22.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.14 |
| Alpha | -66.89 |
| Character TTM | |
|---|---|
| Beta | 1.615 |
| Beta Downside | 3.359 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.35% |
| CAGR/Max DD | 0.26 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
volatile
Description: CORT Corcept Therapeutics March 05, 2026
Corcept Therapeutics is a biopharmaceutical company focused on developing treatments for severe endocrine, oncology, metabolic, and neurological disorders.
The company markets Korlym, an oral medication for hyperglycemia in adults with Cushings syndrome and type 2 diabetes or glucose intolerance, particularly when surgery is not an option. This product targets a niche market within the pharmaceutical sector, focusing on specific patient populations with complex conditions.
Corcept also has several drug candidates in development, including relacorilant for hypercortisolism, miricorilant for metabolic dysfunction-associated steatohepatitis (currently in Phase 1b trials), and a pipeline of selective cortisol modulators for Lou Gehrigs disease. The biopharmaceutical business model relies heavily on R&D and clinical trials, with significant investment required before product commercialization.
Further research on ValueRay can provide more in-depth analysis of Corcepts pipeline and market position.
Headlines to watch out for
- Korlym sales growth drives revenue
- Relacorilant clinical trial success impacts future revenue
- Research and development expenses affect profitability
- Regulatory approval for new drugs is critical
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 99.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA -6.36 > 1.0 |
| NWC/Revenue: 41.95% < 20% (prev 49.01%; Δ -7.06% < -1%) |
| CFO/TA 0.17 > 3% & CFO 142.0m > Net Income 99.1m |
| Net Debt (-114.4m) to EBITDA (57.1m): -2.00 < 3 |
| Current Ratio: 2.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.9m) vs 12m ago 1.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 90.79% > 50% (prev 80.31%; Δ 10.49% > 0%) |
| Interest Coverage Ratio: -4.92 > 6 (EBITDA TTM 57.1m / Interest Expense TTM -11.2m) |
Altman Z'' 9.04
| A: 0.38 (Total Current Assets 485.5m - Total Current Liabilities 166.1m) / Total Assets 836.7m |
| B: 0.77 (Retained Earnings 643.4m / Total Assets 836.7m) |
| C: 0.07 (EBIT TTM 55.2m / Avg Total Assets 838.6m) |
| D: 3.42 (Book Value of Equity 645.8m / Total Liabilities 188.8m) |
| Altman-Z'' Score: 9.04 = AAA |
Beneish M -3.08
| DSRI: 0.91 (Receivables 59.8m/58.1m, Revenue 761.4m/675.0m) |
| GMI: 1.00 (GM 98.30% / 98.39%) |
| AQI: 0.96 (AQ_t 0.41 / AQ_t-1 0.43) |
| SGI: 1.13 (Revenue 761.4m / 675.0m) |
| TATA: -0.05 (NI 99.1m - CFO 142.0m) / TA 836.7m) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of CORT shares?
As of March 11, 2026, the stock is trading at USD 33.99 with a total of 1,203,332 shares traded.
Over the past week, the price has changed by -5.50%, over one month by -17.72%, over three months by -59.12% and over the past year by -39.73%.
Over the past week, the price has changed by -5.50%, over one month by -17.72%, over three months by -59.12% and over the past year by -39.73%.
Is CORT a buy, sell or hold?
Corcept Therapeutics has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy CORT.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CORT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 65.4 | 92.4% |
| Analysts Target Price | 65.4 | 92.4% |
CORT Fundamental Data Overview March 09, 2026
P/E Trailing = 41.3049
P/E Forward = 95.2381
P/S = 4.7319
P/B = 5.56
P/EG = 0.813
Revenue TTM = 761.4m USD
EBIT TTM = 55.2m USD
EBITDA TTM = 57.1m USD
Long Term Debt = 6.11m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 6.11m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.24b USD (3.60b + Debt 6.11m - CCE 372.2m)
Interest Coverage Ratio = -4.92 (Ebit TTM 55.2m / Interest Expense TTM -11.2m)
EV/FCF = 22.83x (Enterprise Value 3.24b / FCF TTM 141.8m)
FCF Yield = 4.38% (FCF TTM 141.8m / Enterprise Value 3.24b)
FCF Margin = 18.62% (FCF TTM 141.8m / Revenue TTM 761.4m)
Net Margin = 13.01% (Net Income TTM 99.1m / Revenue TTM 761.4m)
Gross Margin = unknown ((Revenue TTM 761.4m - Cost of Revenue TTM 13.0m) / Revenue TTM)
Tobins Q-Ratio = 3.87 (Enterprise Value 3.24b / Total Assets 836.7m)
Interest Expense / Debt = 58.64% (Interest Expense 3.58m / Debt 6.11m)
Taxrate = 21.0% (US default 21%)
NOPAT = 43.6m (EBIT 55.2m * (1 - 21.00%))
Current Ratio = 2.92 (Total Current Assets 485.5m / Total Current Liabilities 166.1m)
Debt / Equity = 0.01 (Debt 6.11m / totalStockholderEquity, last quarter 647.8m)
Debt / EBITDA = -2.00 (Net Debt -114.4m / EBITDA 57.1m)
Debt / FCF = -0.81 (Net Debt -114.4m / FCF TTM 141.8m)
Total Stockholder Equity = 649.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.82% (Net Income 99.1m / Total Assets 836.7m)
RoE = 15.25% (Net Income TTM 99.1m / Total Stockholder Equity 649.7m)
RoCE = 8.42% (EBIT 55.2m / Capital Employed (Equity 649.7m + L.T.Debt 6.11m))
RoIC = 6.72% (NOPAT 43.6m / Invested Capital 649.7m)
WACC = 11.85% (E(3.60b)/V(3.61b) * Re(11.87%) + (debt cost/tax rate unavailable))
Discount Rate = 11.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.97%
[DCF] Terminal Value 66.87% ; FCFF base≈163.4m ; Y1≈176.8m ; Y5≈219.1m
[DCF] Fair Price = 21.30 (EV 2.15b - Net Debt -114.4m = Equity 2.27b / Shares 106.4m; r=11.85% [WACC]; 5y FCF grow 9.27% → 2.90% )
EPS Correlation: 7.16 | EPS CAGR: 0.0% | SUE: -0.60 | # QB: 0
Revenue Correlation: 97.17 | Revenue CAGR: 22.76% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.04 | Chg7d=-0.053 | Chg30d=-0.060 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=0.38 | Chg7d=-0.324 | Chg30d=-0.348 | Revisions Net=+0 | Growth EPS=-53.2% | Growth Revenue=+22.8%
EPS next Year (2027-12-31): EPS=1.61 | Chg7d=-1.269 | Chg30d=-1.457 | Revisions Net=-1 | Growth EPS=+318.8% | Growth Revenue=+27.8%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.4% (Discount Rate 11.9% - Earnings Yield 2.4%)
[Growth] Growth Spread = +4.8% (Analyst 14.3% - Implied 9.4%)
P/E Forward = 95.2381
P/S = 4.7319
P/B = 5.56
P/EG = 0.813
Revenue TTM = 761.4m USD
EBIT TTM = 55.2m USD
EBITDA TTM = 57.1m USD
Long Term Debt = 6.11m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 6.11m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -114.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.24b USD (3.60b + Debt 6.11m - CCE 372.2m)
Interest Coverage Ratio = -4.92 (Ebit TTM 55.2m / Interest Expense TTM -11.2m)
EV/FCF = 22.83x (Enterprise Value 3.24b / FCF TTM 141.8m)
FCF Yield = 4.38% (FCF TTM 141.8m / Enterprise Value 3.24b)
FCF Margin = 18.62% (FCF TTM 141.8m / Revenue TTM 761.4m)
Net Margin = 13.01% (Net Income TTM 99.1m / Revenue TTM 761.4m)
Gross Margin = unknown ((Revenue TTM 761.4m - Cost of Revenue TTM 13.0m) / Revenue TTM)
Tobins Q-Ratio = 3.87 (Enterprise Value 3.24b / Total Assets 836.7m)
Interest Expense / Debt = 58.64% (Interest Expense 3.58m / Debt 6.11m)
Taxrate = 21.0% (US default 21%)
NOPAT = 43.6m (EBIT 55.2m * (1 - 21.00%))
Current Ratio = 2.92 (Total Current Assets 485.5m / Total Current Liabilities 166.1m)
Debt / Equity = 0.01 (Debt 6.11m / totalStockholderEquity, last quarter 647.8m)
Debt / EBITDA = -2.00 (Net Debt -114.4m / EBITDA 57.1m)
Debt / FCF = -0.81 (Net Debt -114.4m / FCF TTM 141.8m)
Total Stockholder Equity = 649.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.82% (Net Income 99.1m / Total Assets 836.7m)
RoE = 15.25% (Net Income TTM 99.1m / Total Stockholder Equity 649.7m)
RoCE = 8.42% (EBIT 55.2m / Capital Employed (Equity 649.7m + L.T.Debt 6.11m))
RoIC = 6.72% (NOPAT 43.6m / Invested Capital 649.7m)
WACC = 11.85% (E(3.60b)/V(3.61b) * Re(11.87%) + (debt cost/tax rate unavailable))
Discount Rate = 11.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.97%
[DCF] Terminal Value 66.87% ; FCFF base≈163.4m ; Y1≈176.8m ; Y5≈219.1m
[DCF] Fair Price = 21.30 (EV 2.15b - Net Debt -114.4m = Equity 2.27b / Shares 106.4m; r=11.85% [WACC]; 5y FCF grow 9.27% → 2.90% )
EPS Correlation: 7.16 | EPS CAGR: 0.0% | SUE: -0.60 | # QB: 0
Revenue Correlation: 97.17 | Revenue CAGR: 22.76% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.04 | Chg7d=-0.053 | Chg30d=-0.060 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=0.38 | Chg7d=-0.324 | Chg30d=-0.348 | Revisions Net=+0 | Growth EPS=-53.2% | Growth Revenue=+22.8%
EPS next Year (2027-12-31): EPS=1.61 | Chg7d=-1.269 | Chg30d=-1.457 | Revisions Net=-1 | Growth EPS=+318.8% | Growth Revenue=+27.8%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.4% (Discount Rate 11.9% - Earnings Yield 2.4%)
[Growth] Growth Spread = +4.8% (Analyst 14.3% - Implied 9.4%)